|
|
Vaccine Detail
|
ESO-1:157-165(165V) Peptide Vaccine |
| Vaccine Information |
- Vaccine Name: ESO-1:157-165(165V) Peptide Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007534
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- NY-ESO-1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04 (NCIT_C2754).
|
| Host Response |
|
|
| References |
NCIT_C2754: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2754]
|
|
